IMGN News and Press, ImmunoGen Inc. From 07/30/21

ImmunoGen, Inc. (IMGN) Q2 2021 Earnings Conference Call July 30, 2021, 08:00 ET Company Participants Courtney O’Konek - Senior Director, Corporate Communications & IR Mark Enyedy - President, CEO & Director Anna Berkenblit - SVP & Chief Medical Officer Susan Altschuller - S...

Image source: The Motley Fool. ImmunoGen, inc (NASDAQ: IMGN) Q2 2021 Earnings Call Jul 30, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript

ImmunoGen (NASDAQ:IMGN) reported a wider second-quarter net loss, partly driven by an increase in research and development expenses in the period. Research and development expenses were $34.6M for the second quarter of 2021, compared with $22.9M for the same period last year. The increase was...

ImmunoGen (NASDAQ:IMGN): Q2 GAAP EPS of -$0.15 beats by $0.03. Revenue of $16.95M (+12.8% Y/Y) misses by $1.97M. CEO comment: "Beyond mirvetuximab, our IMGN632, IMGC936, and IMGN151 programs are progressing as anticipated. Patient accrual continues in our IMGN632 trials in BPDCN and AML, with...

Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Top-line Data from Pivotal SORAYA Trial on Track for Q4 Release Continued Progress in O...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its second quarter operating results. Manag...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...

Results to be Presented in an Oral Session at 2021 ASCO Annual Meeting Combination Demonstrates Strong Anti-Tumor Activity in Patients with High FRα Expression, with a Confirmed Overall Response Rate of 64%, Median Duration of Response of 11.8 Months and Median Progress...

ImmunoGen, Inc. (IMGN) Q1 2021 Earnings Conference Call May 10, 2021, 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications and IR Mark Enyedy - President and CEO Anna Berkenblit - CMO Susan Altschuller - CFO Conference Call Participants John Newman - C...